Roughly $400 billion. That is how much market value Eli Lilly (NYSE:LLY | LLY Price Prediction) has added over the past year, with shares climbing from $773.86 on July 2, 2025 to $1,213.91 on July 2, 2026, a 56.86% gain that has pushed the drugmaker’s market capitalization to $1.063 trillion.
No other Big Pharma name has expanded its footprint by that magnitude in that window. The surge is the market’s verdict on a business that is now selling GLP-1 medicines faster than it can make them, and adding oral formulations, oncology franchises, and immunology drugs on top.
What It Means
This $400 billion gain came on the back of extremely strong execution. In the most recent quarter, Lilly reported Q1 2026 revenue of $19.80 billion, a 55.5% year-over-year jump that beat consensus by 11.25%. Non-GAAP EPS of $8.55 topped the $6.79 estimate by 25.92%, driven by net income which rose 168.04% year-over-year to $7.40 billion, and operating income which climbed 64.84% to $8.92 billion.
Two products are doing the heavy lifting. Mounjaro generated $8.66 billion in the quarter, up 125% year-over-year. Zepbound delivered $4.16 billion, with U.S. revenue up 80%.
Beneath the incretin franchise, Jaypirca rose 79% to $165 million, Ebglyss climbed 141% to $145 million, and Omvoh grew 115% to $80 million. Volume across the business rose 65%, offsetting a 13% decline in realized prices.
On top of this, international revenue expanded 81% to $7.70 billion, showing Lilly is scaling globally rather than leaning on a single home market.
Market Reaction
Shares of LLY stock are up 14.07% over the past month and 7.65% over the past week, closing at $1,213.91 on July 2, 2026, a 1.86% daily gain. Year-to-date the stock is up 13.34%, and the five-year return sits at 443.8%. LLY is now trading roughly 1% below its 52-week high of $1,238.
Bull Case
The bull case for Eli Lilly rests on three pillars: earnings power, pipeline breadth, and management conviction. On earnings, Lilly has delivered four consecutive beats, with the 25.92% Q1 2026 surprise the largest in the streak. Reported EPS has climbed from $6.31 in Q2 2025 to $7.02, $7.54, and $8.55 across the following three quarters. Management raised full-year 2026 guidance to $82.0 billion to $85.0 billion in revenue and non-GAAP EPS of $35.50 to $37.00, with a performance margin of 47.0% to 48.5%.
In terms of the company’s pipeline, the FDA approved Foundayo (orforglipron), the only approved GLP-1 pill that can be taken any time of day without food and water restrictions. Orforglipron also beat oral semaglutide in a head-to-head type 2 diabetes trial published in The Lancet. Retatrutide delivered positive Phase 3 data in T2D, and Lilly added four acquisitions in the quarter: Orna Therapeutics, Centessa Pharmaceuticals, Kelonia Therapeutics, and Ajax Therapeutics.
On conviction, there’s plenty. Four of Eli Lilly’s directors bought stock together on June 15, 2026 at $1,129.35, following prior coordinated purchases at $988.09 in May and $919.90 in April. Buying at rising prices signals conviction. CEO David Ricks framed the quarter this way: “2026 is off to a strong start, we delivered 56% revenue growth in the first quarter and raised our full-year revenue guidance by $2 billion.”
Bottom Line
For long-term holders, the $400 billion in added market value reflects a business compounding at rare speed for a company already the size of Lilly. Risks exist, though. With $584 million in acquired IPR&D charges, $279 million in litigation charges, tariff exposure, and the 13% price give-back on incretins, there’s plenty for investors to consider. That’s on top of a forward P/E of 33 leaves little room for disappointment.
Thus, I think the next catalyst investors have on the calendar is Lilly’s Investment Community Meeting on December 7, 2026, with an ex-dividend date of August 14, 2026 in between. A trillion-dollar drugmaker growing revenue at 56% is a rare data point in pharma. That is what $400 billion buys you.
Contact [email protected] for any questions or corrections.
Top Gaining Stocks
Top Losing Stocks